A cross-border seroprevalence study on HBV, HCV, HDV and HIV in remote Amazonian communities on the border between French Guiana and Suriname Authors: Roxane Schaub, M. Sigrid MacDonald–Ottevanger, Stella Hoang, Amandine Pisoni, Karine Bolloré, Barbara Biche, Anfernee Neus, Rikesh Bisnajak, Janke Schinkel, Julie Blanc, Antoon Grunberg, Richard Naldjinan, Aude Lucarelli, Cyril Rousseau, Céline Michaud, Melanie Gaillet, Soeradj Harkisoen, Emmanuel Gordien, Maria Prins, Edouard Tuaillon, Mathieu Nacher, Stephen Vreden, Getu Girmay, Getu Girmay, Getu Girmay, Getu Girmay Published: 2026 ABSTRACT BackgroundNational epidemiological data are essential to achieve viral hepatitis elimination goals. However, viral hepatitis and HIV epidemiology in French Guiana (FG) and Suriname is mainly limited to urban areas. We therefore assessed the prevalence, associated determinants, and knowledge, attitudes, practices, and beliefs (KAP-B) regarding hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and HIV in the isolated area of the Maroni River, bordering FG and Suriname.MethodsBetween January 2018 and February 2019, adults (≥18 years) living along the Maroni were enrolled in this cross-sectional study and completed a risk factor and KAP-B questionnaire. Participants were tested for viral hepatitis and HIV using serological and molecular analyses: HBV (HBsAg, anti-HBcore antibodies, anti-HBs, HBV DNA), HCV (HCV-antibodies, HCV RNA), HDV (HDV-antibodies), and HIV (HIV-antibodies/antigen, HIV RNA). Age- and sex-adjusted HBV, HCV, and HIV prevalences were estimated using post-stratification weighting.FindingsAmong 2286 participants, adjusted prevalences were respectively 2.08% (95%CI: 1.49–2.66; n = 46) for HBsAg, 25.6%, (95%CI: 20.89–29.24, n = 646) for resolved HBV infection (negative HBsAg and positive anti-HBcore antibodies), 0.13% (95%CI: 0.0–0.27; n = 5) for HCV-antibodies, and 0.65% (95%CI: 0.0–1.40; n = 12) for HIV-antibodies. There were no HDV infections. HBV exposure (acute or resolved) was independently associated with age (per 10-year increase aOR:1.27, 95%CI: 1.18–1.37, p < 0.0001), males (aOR:1.34, 95%CI: 1.10–1.65, p = 0.006), Maroon (aOR:2.22, 95%CI: 1.27–4.06) or other ethnic groups (aOR:2.94, 95%CI: 1.61–5.59) versus Amerindians, (p = 0.002), and higher education (aOR:0.71, 95%CI: 0.56–0.90, p = 0.005). Older age (per 10-years increase aOR:1.64, 95%CI: 1.11–2.44), p = 0.01) and non-autochthonous origin (aOR:3.81, 95%CI: 1.14–12.26, p = 0.02) were associated with HIV. Less than one in six participants correctly identified viral hepatitis transmission modes.ConclusionHBV, HCV and HIV prevalences along the Maroni River were comparable to urban areas and remain concerning. Knowledge about viral hepatitis was low. Achieving viral hepatitis elimination goals requires awareness campaigns and test-and-treat strategies tailored to hard-to-serve populations. Introduction The HIV epidemic has led to thousands of cumulative deaths on the Guiana Shield, where HIV was introduced in the 1970s and soared in the 1990s with multidirectional circulation [1]. French Guiana (FG) and Suriname, both situated on the Guiana Shield, have similar HIV prevalence estimates: 1.2%−1.4% of the total population in 2016 [2] and 1.6% (95% confidence interval (95%CI): 1.3–1.9), respectively, in adults aged 15–49 years in 2022 [3]. Transmission is predominantly heterosexual (87.7%), followed by unspecified (8.7%) and mother-to-child transmission (MTCT, 1.9%) [4], AIDS and HIV-related mortality have, however, substantially decreased, most likely as a result of increased availability of combination antiretroviral therapy (cART), early treatment initiation, and upscaling of preventive measures campaigns (HIV screening, Treatment as Prevention (TasP), Pre-Exposure Prophylaxis (PrEP) awareness, condom-use). Recent efforts have broadened the focus of HIV programs towards sexual health and sexually transmitted infections [5], and prevention of mother-to- child transmission, notably including hepatitis B (HBV) [6]. Countries on the Guiana Shield share a setting wherein most of the population lives in urban areas along a narrow coastal strip while the rest lives in scattered small villages in the vast interior, most of which is covered by Amazonian forest. Both countries also share a richness in gold in the interior, which attracts tens of thousands of mostly undocumented, artisanal gold miners with a particular social organization around the mines, notably sex work [7]. Interestingly, on the rural border region between French Guiana and Suriname, the Maroni, a recent study showed a 0.52% HIV prevalence (95%CI: 0.45–0.59), far lower than the overall HIV prevalence in both countries. Given the paucity of information on the Maroni, it is unknown if this variation in prevalence is also seen in viral hepatitis. In the more urban areas of FG and Suriname, HBV prevalence oscillates around 3%, with varying prevalence across genders and ethnic groups [8–11] and HCV prevalence varies between 0.2% to 1.1% in FG [9] and is estimated at 1.0% in Suriname [12], with significant differences in gender and ethnic groups. However, a recent study in rural villages in the north east of Suriname, showed a much higher HCV prevalence of 5.9% (95%CI: 1.5–10.3) [10]. These variations emphasize the need to conduct epidemiological research nationwide in order to fully comprehend the dynamics of a disease, including differences in populations and geographical areas, and the influence of cultural customs. We therefore aimed to assess viral hepatitis in a large rural border region between Suriname and French Guiana. Apart from the towns of Albina (5,247 inhabitants) and Saint-Laurent-du-Maroni (45,000 inhabitants), the 520 km long border between Suriname and FG is mostly unenforced (Fig 1), and consists of Amazonian forest where villages on either side of the Maroni River can only be reached by canoe or small aircraft. Most of the population consists of Maroon tribes -descendants of West-Africans, who escaped enslavement-, and indigenous tribes. The population of Eastern Suriname is around 31,000 persons and that of Western FG is around 90,000 persons and growing rapidly [4]. The border river is mostly symbolic, with relatives living on both shores, leading to frequent cross-border migration and travel to Saint-Laurent-du-Maroni, the main town in the Maroni basin [13]. In this urban hub of Western FG, the prevalence of HBsAg seropositivity between 2012 and 2016 was 2.1%; 1.1% in women and 3.7% in men [4]. Ethnic communities and healthcare posts along the Maroni River, border between Suriname and French Guiana. Reprinted from [14] under a CC BY license, with permission from the original authors, original copyright 2012; modified by the authors of this work. In this remote area, health care is provided through health clinics in the main villages (Fig 1), some sites staffed by doctors whereas others are staffed by nurses [4]. Knowledge, attitudes, practices and beliefs (KAP-B) surveys have shown a high prevalence of high-risk sexual behavior, and infrequent sexual interactions between Amerindians and Maroon communities [15]. In the 1990s, the HIV epidemic surged from zero to over 1% prevalence among pregnant women on the Maroni [16]. MTCT is an estimated 0.7% between 2013–2022 in FG [16] and 1.8% in 2014 in Suriname [6]. This, coupled with various cultural practices, including subcutaneous penile implants (bugrus) [17], vaginal steam baths -which can lead to disruption of mucosal integrity [18] and a matriarchal society with migrant and sometimes polygamous men, led to the perception that prevalence of sexually transmitted infections (STI) in this region, is high. However, data are insufficient to validate this hypothesis. The study of viral hepatitis prevalence along the Maroni River (MaHeVi) hence took place in a large strip of rural villages in an Amazonian context, with a complex and interesting network of transnational relations. This included the mobile migrant population, mainly of Brazilian origin [19], living in the semi-permanent artisanal and small goldmining areas in this strip. The main objective was to estimate the prevalence of hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and HIV in the adult population on both the FG and Surinamese side of the Maroni River. The secondary objectives of the study were to assess KAP-B about viral hepatitis, and to identify specific determinants for an HBV, HCV, HDV, or HIV infection. Materials and methods Study design and population The MaHeVi prevalence study was population-based, cross-sectional, multicentric, non-interventional, and minimally invasive. Participants, aged 18 years or older, living along the Maroni River in FG or Suriname, upstream from Apatou (Fig 1), planning to stay in the area for at least two months after inclusion, and providing informed consent, were recruited in French Guiana from the 16th January 2018–23rd November 2018 and in Suriname from 14th January 2018–8th February 2019, on a voluntary basis, following extensive preparation and a vast information campaign. No further exclusion criteria were applied beyond the inclusion criteria specified above. Carrying out a study in such a logistically and culturally challenging context called for appropriate planning and communication to ensure adequate information and gain the support of local populations in a context where mistrust of researchers is commonplace. We have described this preparation in detail elsewhere [20]. Participants completed a standardized structured questionnaire, available in local languages, which was developed based on information from focus groups and in-depth interviews done by anthropologists in the preliminary study [20]. Due to cultural and linguistic specificities and lower literacy levels in the interior, questionnaires were administered by trained cultural mediators. Subsequently, blood samples were collected for viral hepatitis screening and, optionally, HIV. We chose the opt-out option for HIV testing based on data indicating this may increase test acceptance rate [21]. Testing methods and laboratory analyses We used Dried Blood Spots (DBS) instead of conventional venous blood sampling for logistical and acceptability reasons [22]. Indeed, access to centrifugation facilities and refrigerated storage space was mostly non-existent, and timely sample transfer to a fully equipped laboratory was not guaranteed. Seven drops of capillary blood obtained by finger prick were collected by a trained nurse on a blotting paper Whatman 903™ Protein Saver Cards (Whatman GmbH, Dassel, Germany). After drying, the DBS were stored at 4°C while in the field, transported in an icebox to Cayenne, stored at −20°C and sent on dry ice to Montpellier for laboratory analysis. HBV, HCV, HDV, and HIV serologies were performed, and in case of a positive result, viral load was measured. All laboratory analyses were done at the laboratory of Virology, Montpellier University Hospital, France. For serologies, eight punches of 6 mm in diameter were eluted in 1000 µL of PBS and for molecular analyses, two punches of 6 mm in diameter were eluted in 240 µL of PBS-BSA (10%)/ Tween20 (0.05%) buffer solution. HBV and HCV extraction were performed in accordance with the manufacturer’s instructions, with respectively QIAamp® DNA Mini Kit and QIAamp® RNA Mini Kit (QIAGEN, Hilden, Germany). Serological testing for HBV, HCV, HIV and HDV was performed using commercial assays according to the manufacturers’ instructions. Whenever applicable, manufacturer-recommended cutoffs were used. For some assays, these thresholds were adjusted for DBS eluates, as the kits were validated for serum samples and may be subject to DBS-related matrix effects. Specific cutoff values for each assay are provided in S2 Table. Hepatitis B virus serology and molecular analysis. Samples were tested for hepatitis B using LIAISON® XL Murex HBsAg Quant kit (DiaSorin, Saluggia, Italy) for Hepatitis B Surface Antigen (HBsAg). For Hepatitis B surface antibodies (anti-HBs Ab) and anti-HBc antibodies (anti-HBc Ab), two assay kits were used for the same serology during the study period, following platform replacement: LIAISON® XL Murex Anti-HBs kit (DiaSorin, Italy), followed by Alinity i Anti-HBs Reagent Kit (Abbott, Chicago, IL, USA); and ADVIA Centaur® HBc Total kit (Siemens, Tarrytown, NY, USA) followed by Alinity i Anti-HBc II Reagent Kit (Abbott, USA), respectively. The detection limit of anti-HBs Ab on DBS samples was estimated at 50 IU/mL. All HBsAg positive samples were further tested for hepatitis B e-antigen (HBe) using LIAISON® XL Murex HBeAg kit (DiaSorin, Italy) and HBV DNA detection and quantification using PUMA HBV real time PCR kit (Omunis, Clapiers, France). Serologies were interpreted according to possible infection status: (i) acute/chronic HBV infection: positive HBsAg and positive anti-HBc Ab; (ii.) resolved hepatitis: negative HBsAg and positive anti-HBc Ab; (iii) HBV exposed: anti-HBc Ab positive regardless of HBsAg status, (iv) HBV vaccinated if anti-HBs positive and all other markers negative; (v) HBV susceptible if all markers are negative. Hepatitis C virus serology and molecular analysis. Samples were tested for anti-HCV antibodies (anti-HCV Ab) using LIAISON® XL MUREX HCV Ab kit (DiaSorin, Italy). Positive samples were tested for HCV RNA detection and quantification using PUMA HCV real time RT-PCR kit (Omunis, Clapiers, France). Hepatitis D virus serology. HBsAg positive samples were tested for anti-HDV antibodies (anti-HDV Ab) using ETI-AB-DELTAK-2 (EIA) anti-HDV assay (DiaSorin, Italy). HIV serology. Samples were tested using HIV p24 antigen and HIV antibodies (HIV Ab) with fourth-generation combined EIA LIAISON® XL MUREX HIV Ab/Ag kit (DiaSorin, Italy) and if positive, confirmed by HIV-Ab positivity and determination of HIV-1, HIV-2, or HIV-1/2 infection with the Geenius™ HIV1/2 Confirmatory Assay (Bio-Rad, France). Determinants of HBV, HCV, HDV, and HIV infection, and KAP-B regarding HBV and HCV infection Through the standardized interviewer-led questionnaire, we recorded self-reported social and demographic characteristics of participants, known or potential determinants associated with HBV, HCV, HDV, and HIV infection, e.g., unsafe sex practices: early sexual initiation, multiple sex partners during the last year, not using a condom during the last intercourse, transactional sex during the last intercourse, lifetime history of STIs or bleeding during intercourse; alcohol (Alcohol Use Disorders Identification Test-Concise (AUDIT-C test [23]) and (injecting) drug-use (IDU). Body modifications (tattoos and piercings, and whether they were performed in regulated or unregulated conditions); cultural practices, e.g., koti- a traditional medical practice involving scarification followed by application of medicine- and penile implants (bugrus), all performed with potentially unsterilized equipment, vaginal steam baths using astringent plants; previous blood transfusions or dialysis; and sharing personal hygiene equipment such as toothbrushes, razors or nail clippers. were also evaluated as potential determinants of these infections. KAP-B regarding HBV and HCV infections were assessed using a standardized closed questionnaire, with “yes”, “no”, or “do not know/maybe” answers. Participants were assigned an ethnic group based on their mother tongue, as described previously in studies done on the Maroni River [15]. Sample size For HBV, to get a precision of 0.7% as expressed by the 95% CI in estimating an expected HBsAg seropositivity prevalence of 3%, we needed to include 2282 participants. For HCV, the sample size corresponding to 0.4% precision in estimating an expected HCV prevalence of 1%, is 2377. We therefore, aimed to include a total of 2500 persons along the Maroni River (approximately 12% of the targeted population), which enabled us to achieve sufficient precision in our prevalence estimates. Statistical analysis Categorical variables were described as frequencies and percentages, and continuous variables as means with standard-deviations (SD), or medians with interquartile range (IQR) or range, depending on the distribution. We calculated the HBV, HCV, and HIV prevalence, and their corresponding 95% CI, corrected by post-stratification weighting to correct for sampling selection bias. Post-stratification weighting was carried out on the population structure in terms of age and sex of each geographical unit, based on 2012 census data from Suriname (for each resort) and 2018 census data for French Guiana (for each municipality). We compared participant characteristics across HBV exposure groups (acute or chronic infection, or resolved infection), acute or chronic HCV infection, and HIV infection. Risk-factor analyses focused on HBV-exposed versus HBV-susceptible individuals, and HIV-positive versus HIV-negative individuals; determinants of HCV infection were not evaluated due to the very small number of HCV cases. Odds ratios (ORs) and 95% CIs were computed using bivariable logistic regression, and linearity of continuous variables was assessed. Variables with p < 0.15 in bivariable analyses were entered into the multivariable model. Those with >20% missing data or with counterintuitive associations (e.g., protective effects of piercings, or toothbrush sharing) were excluded. Collinearity among covariates was examined in both the full and final models. Variables were then manually removed using a backward procedure, starting with the least significant, until only those with p < 0.05 remained. Model fit was evaluated using the Hosmer–Lemeshow test. For HIV analyses, bivariable and multivariable logistic regressions were performed using the Firth correction for rare events [24]. A p-value<0.05 was considered statistically significant. Statistical analyses were conducted using SAS software Version 9.4 (SAS Institute Inc., Cary, NC, USA). Ethical and regulatory aspects The MaHeVi study (ClinicalTrials.gov Identifier: NCT05002907) was approved by the Ethics Committee of the Ministry of Health of Suriname (VG 023–16) and by the Comité d’Evaluation Ethique de l’Institut National de la Santé et de la Recherche Médicale (IRB00003888). All participants provided written informed consent prior to their inclusion in the study. Results were delivered individually and confidentially to participants by the study doctors or the general practitioner at their respective health care center within 4–6 weeks after testing, allowing participants with positive results to be followed and treated according to standard clinical care of the participating country. All samples were centralized and stored by the CRB Amazonie, the biobank of Cayenne Hospital Center. Results We included 2289 participants between January 2018 and February 2019. Three participants were excluded due to an empty or lost questionnaire hence a total of 2286 participants were analyzed. Six percent (n = 134) participants opted out HIV-testing. There were significant differences in country of birth and residence, and educational level between participants who opted out for HIV testing compared to those that did not. There were no differences in sex, age, work, or other determinants. S1 Table shows inclusion numbers by site and by country. Study population There were slightly more women included in the study (56.3%, n = 1285) than men, and the mean age (±SD) was 42.8 ± 14.4 years (Table 1). The majority of the participants (72.7%) spoke one of the Maroon languages, mainly Ndjuka, and 8.3% spoke one of the Amerindian languages, primarily Wayana. Almost 60% (n = 1319) had no formal education or only primary education. Table 2 describes known and potential determinants, including substance use, medical history, body modifications, and sexual behavior in the MaHeVi population, according to viral hepatitis and HIV infection. 10.1371/journal.pone.0344187.t001Table 1Socio-demographic characteristics of the MaHeVi study population along the Maroni river.Socio-demographic characteristicsStudy populationHBV infection(HBsAg +)Resolved HBV infectionHCV infectionHIV infection&n (%) or mean ± SD (range)(n = 2286)(n = 46)(n = 646)(n = 5)(n = 12) Sex Male998 (43.7)26 (56.5)297 (46.0)4 (80.0)6 (50.0)Female1285 (56.3)20 (43.5)349 (54.0)1 (20.0)6 (50.0) Age in years 42.8 ± 14.4 (18-95)40.9 ± 13.1 (23-88)47.5 ± 15.0 (18-92)59.0 ± 7.8 (53-68)52.3 ± 13.0 (35-79) Mother tongue (Ethnicity) Maroon*1655 (72.7)36 (78.3)513 (79.5)2 (40.0)7 (58.3)Amerindian†189 (8.3)1 (2.2)17 (2.6)0 (0)0 (0)French45 (2.0)0 (0)3 (0.5)2 (40.0)0 (0)Dutch27 (1.2)1 (2.2)10 (1.6)0 (0)1 (8.3)Portuguese231 (10.1)6 (13.0)65 (10.1)0 (0)3 (25.0)Other132 (5.8)2 (4.4)37 (5.7)1 (20.0)1 (8.3) Country of birth French Guiana766 (33.6)16 (34.8)154 (23.9)2 (40.0)4 (36.4)Suriname1175 (51.5)22 (47.8)403 (62.5)2 (40.0)4 (36.4)Brazil245 (10.7)6 (13.0)68 (10.5)0 (0)3 (27.3)Other94 (4.1)2 (4.4)20 (3.1)1 (20.0)0 (0) Country of residence French Guiana1422 (62.4)27 (58.7)350 (54.5)3 (60.0)6 (50.0)Suriname841 (36.9)19 (41.3)291 (45.3)2 (40.0)6 (50.0)Other15 (0.7)0 (0)1 (0.2)0 (0)0 (0) School level Never been to school797 (35.4)16 (34.8)272 (42.6)1 (25.0)5 (41.7)Primary522 (23.2)13 (28.3)166 (26.0)1 (25.0)3 (25.0)Middle school484 (21.5)8 (17.4)127 (19.9)1 (25.0)2 (16.7)High school356 (15.8)6 (13.0)62 (9.7)1 (25.0)2 (16.7)Higher education91 (4.0)3 (6.5)11 (1.7)1 (25.00 (0) Professional activity Don’t work985 (43.5)16 (35.6)285 (44.3)0 (0)5 (41.7)Work1257 (55.5)29 (64.4)354 (55.1)5 (100)7 (58.3)Student/Training23 (1.0)0 (0)4 (0.6)0 (0)0 (0)HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, HIV: human immunodeficiency virus, SD: Standard Deviation; *Ndjuka, Aluku, Pamaka, Saramaka; †Wayana, Teko, Trio, Apalai; & Denominator: 2152 participants opted in for HIV testing. Percentages are calculated excluding missing data – percentages add up to 100%. Socio-demographic characteristics of the MaHeVi study population along the Maroni river. HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, HIV: human immunodeficiency virus, SD: Standard Deviation; *Ndjuka, Aluku, Pamaka, Saramaka; †Wayana, Teko, Trio, Apalai; & Denominator: 2152 participants opted in for HIV testing. Percentages are calculated excluding missing data – percentages add up to 100%. 10.1371/journal.pone.0344187.t002Table 2Hepatitis B, C and HIV determinants in the MaHeVi study population along the Maroni River.HBV, HCV, and HIV known or suspected determinantsStudy populationHBV infection (HBsAg +)Resolved HBV infectionHCV infectionHIV infectionn (%) or median [IQR](n = 2286)(n = 46)(n = 646)(n = 5)(n = 12) Alcohol and drugs Alcohol use disorders (positive AUDIT-C# test) 578 (27.6) 14 (34.2) 128 (21.3) 2 (40.0) 2 (16.7) Drug use during the past month 199 (8.8) 5 (11.1) 59 (9.2) 3 (60.0) 1 (8.3) marijuana159 (7.0)5 (11.1)41 (6.4)2 (40.0)1 (8.3)crack22 (1.0)0 (0)11 (1.7)0 (0)0 (0)cocaine5 (0.2)0 (0)4 (0.6)0 (0)0 (0)other drug36 (1.6)1 (2.2)14 (2.2)1 (20.0)0 (0) Injection drug use (ever) 15 (0.7) 0 (0) 3 (0.5) 2 (50.0) 0 (0) Health care and nosocomial risks Blood transfusion & 280 (12.4) 5 (11.1) 81 (12.7) 1 (20.0) 2 (18.2) before 199037 (1.7)0 (0)15 (2.4)1 (20.0)1 (9.1)1990-200047 (2.1)0 (0)19 (3.0)0 (0)1 (9.1)>2000168 (7.6)4 (9.1)35 (5.5)0 (0)0 (0)unknown year15 (0.7)1 (2.3)8 (1.3)0 (0)0 (0) Dialysis 54 (2.4) 0 (0) 16 (2.5) 0 (0) 0 (0) Dental care outside of official health care facility 277 (12.3) 2 (4.4) 85 (13.3) 3 (60.0) 1 (8.3) at home/with a friend38 (1.7)0 (0)13 (2.1)0 (0)0 (0)in a shop/traveling practitioner183 (8.2)2 (4.4)58 (9.2)3 (60.0)1 (8.3) Sexual risk factors Age at first sexual encounter 16 [14-18] 16 [15-18] 16 [14-18] 17 [14-19] 16 [13-17] In a polygamous relationship 306 (21.6) 6 (22.2) 957 (24.7) 0 (0) 1 (14.3) Several partners in last year 414 (23.1) 10 (27.0) 112 (22.5) 2 (50.0) 1 (11.1) 2-3 partners212 (12.3)5 (14.3)56 (11.6)0 (0)1 (11.1)≥4 partners138 (8.0)3(8.6)40 (8.3)2 (50.0)0 (0) Casual partner (last intercourse) 387 (19.1) 8 (19.5) 100 (17.6) 3 (75.0) 2 (18.2) No condom use (last intercourse) 1456 (70.2) 30 (69.8) 411 (71.1) 2 (40.0) 7 (63.6) Transactional sex** (last intercourse) 139 (7.3) 6 (15.0) 41 (7.7) 0 (0) 2 (22.2) History of STI (lifetime) 310 (14.3) 8 (18.6) 86 (13.9) 4 (80.0) 2 (16.7) Sex with same-sex partner (lifetime) 36 (1.6) 1 (2.3) 8 (1.3) 0 (0) 0 (0) Bleeding during intercourse^ (lifetime) 109 (11.3) 3 (23.1) 24 (10.3) 0 (0) 1 (20.0) Had/have bugrus (men) or partner with bugrus 234 (13.5) 7 (20.0) 66 (15.5) 0 (0) 0 (0) Customs, rituals, hygiene, and cosmetic risks Vaginal steam baths ^ 974 (80.5) 13 (81.3) 292 (87.7) 1 (100) 4 (66.7) everyday707 (59.7)11 (73.3)215 (66.0)1 (100)1 (16.7)regularly/after periods218 (18.4)1 (6.7)63 (19.3)0 (0)3 (50.0)after childbirth only24 (2.0)0 (0)7 (2.2)0 (0)0 (0) Scarification (koti) 166 (7.7) 1 (2.3) 55 (9.1) 1 (20.0) 0 (0) Tattoos 535 (23.6) 10 (21.7) 128 (20.0) 3 (60.0) 0 (0) At least 1 done in an unregulated setting358 (15.8)7 (15.2)89 (13.9)2 (40.0).All done in regulated setting177 (7.8)3 (6.5)39 (6.1)1 (20.0). Piercings 1504 (66.3) 27 (58.7) 401 (62.9) 3 (60.0) 5 (41.7) At least 1 done in a non-regulated setting1283 (56.5)20 (43.5)346 (54.2)3 (60.0)5 (41.7)All done in regulated setting221 (9.7)7 (15.2)55 (8.6)0 (0)0 (0) Sharing of toothbrushes 214 (9.4) 3 (6.5) 34 (5.3) 0 (0) 0 (0) Sharing of nail clippers 878 (39.0) 18 (39.1) 223 (35.2) 2 (40.0) 2 (16.7) Sharing of razor/epilator 200 (8.9) 5 (11.1) 44 (7.0) 1 (20.0) 0 (0) HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, HIV: human immunodeficiency virus, IQR: Inter quartile range, STI: sexually transmitted infections; #Positive AUDIT-C test: score ≥3 for women and ≥4 for men; **Transactional sex was defined as having paid for or having been paid in exchange for sex; ^Female only determinant; &In Suriname, blood products are screened for HBV and HIV since 1988 and for HCV since 1998; in French Guiana, blood products are screened for HBV, HIV, and HCV since 1971, 1985, and 1990 respectively; Percentages are calculated excluding missing data – and add up to 100%. Hepatitis B, C and HIV determinants in the MaHeVi study population along the Maroni River. HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, HIV: human immunodeficiency virus, IQR: Inter quartile range, STI: sexually transmitted infections; #Positive AUDIT-C test: score ≥3 for women and ≥4 for men; **Transactional sex was defined as having paid for or having been paid in exchange for sex; ^Female only determinant; &In Suriname, blood products are screened for HBV and HIV since 1988 and for HCV since 1998; in French Guiana, blood products are screened for HBV, HIV, and HCV since 1971, 1985, and 1990 respectively; Percentages are calculated excluding missing data – and add up to 100%. Prevalence of hepatitis B, C, D, and HIV, and HBV vaccination status Crude DBS results are presented in S2 Table. Overall, 2.01% (95%CI: 1,48–2.67; n = 46) participants tested positive for HBsAg, and 2.61% and 1.56% for men and women respectively (p = 0.08). After post-stratification weighting, the adjusted prevalence estimate for HBsAg seropositivity was 2.08% (95%CI: 1.49–2.66). Almost half of HBsAg seropositive participants (n = 20) had a detectable HBV VL; (median: 8.7909 IU/mL; IQR: 147−3,03.107), and five had a positive HBeAg. None of the HBsAg-positive participants had an HDV coinfection. More than a quarter of the participants (28.3%, n = 646; adjusted prevalence 25.06% (95%CI: 20.89–29.24) had anti-HBc Ab who tested HBsAg seronegative, of which 51.6% (n = 333) had detectable anti-HBs Ab). A total of 23.5% (n = 538) had serological evidence of HBV vaccination, 43.1% (n = 985) were susceptible to HBV infection, having no HBV serological markers, 0.9% (n = 21) had no markers of infection but an unknown anti-HBs Ab serology, and 2.2% (n = 50) had an HBV serology that was difficult to interpret (S3 Table). Excluding participants who had a non-interpretable HBV status, 27.14% (95%CI: 22.74–31.54; n = 692) are or were infected with HBV, i.e., HBV exposed. Five participants had anti-HCV Ab (0.22%), corresponding to an adjusted HCV seroprevalence of 0.13% (95%CI: 0.00–0.27), of which four had a detectable HCV viral load (range: 52.100–422.000 IU/mL); one woman and four men tested anti-HCV positive. Two anti-HCV positive participants were of Maroon descent, two of French descent and one of other descent. Most participants (94%; n = 2152/2286) opted-in for HIV testing; 13/2152 had anti-HIV Ab, of which 12 were confirmed with the Geenius Confirmatory Assay, corresponding to an adjusted prevalence of 0.65% (95%CI: 0.00–1.40) overall, and a 0.54% prevalence among 18–49 years old. HIV prevalence was 0.64% in males and 0.50% in females (p = 0.30), and 1.36%, 0.45% and 0% in participants of Brazilian, Maroon, and Indigenous descent, respectively, and 1.05% in participants from other descent. There were no co-infections. 23.5% (n = 538) of participants had DBS serological markers indicating an effective vaccination (S3 Table). Vaccinated participants were significantly younger (39 years old, IQR [30–50]) compared to susceptible participants and participants with a current or resolved HBV infection (43 years old [32–53]; p < 0.001). Participants from Amerindian descent were more frequently vaccinated (57.2%; n = 95), compared to Maroon (18.0%, n = 291) or other participants (34.9%, n = 149; p < 0.0001). Participants with a middle school education level or higher, were more likely to be vaccinated (30.3%, n = 275), compared to participants who did not go beyond primary school (19.7%; n = 251; p < 0.001). Determinants of HBV exposure, HCV infection, and HIV infection In multivariable analysis, age, sex, ethnicity, and educational level were significantly associated with HBV exposure, compared to those who were HBV-susceptible (Table 3). Older age was significantly associated with HBV exposure (per 10-year increase, aOR:1.27, 95%CI: 1.18–1.37, p < 0.0001). Males had significantly higher odds of HBV exposure compared to females (aOR:1.34, 95%CI: 1.10–1.65, p = 0.006), and those of Maroon or other ethnicity had higher odds of HBV exposure compared to those of Amerindian descent – aOR:2.22 (95%CI: 1.27–4.06) and aOR:2.94 (95%CI: 1.61–5.59) respectively (p = 0.002). Participants with a higher education level had significantly lower odds of HBV exposure compared to those with a lower education level (aOR:0.71, 95%CI: 0.56–0.90, p = 0.005). Although being in a polygamous relationship was significantly associated with HBV exposure in bivariable analysis, due to more than 20% missing answers, this determinant was not included in the multivariable model. Alcohol and drug use, nosocomial determinants – blood transfusion, dialysis, and dental care in non-regulated setting, potential sexual risk factors – early sexual initiation, condomless sex, transactional sex, history of STI (lifetime), same-sex partner, bleeding during intercourse and having bugrus, and traditional customs – vaginal steam baths and scarification – tattoos, piercings, and sharing of toothbrushes, nail clippers or razors/epilators were not associated with increased odds of HBV exposure. Subgroup analyses stratified by sex (S4 Table) and ethnic group (S5 Table) revealed broadly similar associations, although the magnitude and significance of these factors differed between subgroups. 10.1371/journal.pone.0344187.t003Table 3Logistic regression models for risk factors of HBV exposure along the Maroni.Known or suspected risk factorsHBV-susceptibleHBV-exposedBivariable modelsMultivariable model(N analyzed in bivariable analyses)N (%) or median [IQR]OR [95%CI], p-valueaOR [95%CI], p-valueFor HBV exposure (n = 1677)(n = 985)(n = 692)(n = 1599)Age (n = 1626)(per 10-year increase)40 [30-50]46 [36-57] 1.32 [1.23–1.41], p < 0.0001 1.27 [1.18–1.37], p < 0.0001 SexMale405 (41.2)323 (46.7) 1.25 [1.03–1.52], p = 0.027 1.34 [1.10–1.65], p = 0.006 (n = 1674)Female (RG)577 (58.8)369 (53.3) – Mother tongueMaroon775 (78.9)549 (79.5) 2.09 [1.21–3.60], p = 0.008 2.22 [1.27–4.06], p = 0.007 (n = 1673)Other154 (15.7)124 (18.0) 2.37 [1.32–4.25], p = 0.004 2.94 [1.61–5.59], p = 0.0007 Amerindian (RG)53 (5.4)18 (2.6) - (global p = 0.015) - (global p = 0.002) Education levelMiddle/High/University416 (42.9)217 (31.7) 0.62 [0.50–0.76], p < 0.0001 0.71 [0.56–0.90], p = 0.005 (n = 1654)No education/Primary (RG)554 (57.1)467 (68.3) – –In a polygamous relationshipYes118 (19.4)103 (24.5) 1.35 [1.00–1.82], p = 0.049 >20% missing data(n = 1029)No (RG)491 (80.6)317 (75.5) – –PiercingAt least 1 done in unregulated setting378 (38.6)318 (46.5) 0.72 [0.59–0.88], p = 0.013 not relevant(n = 1664)None or done in regulated setting (RG)602 (61.4)366 (53.5) – –Sharing toothbrushYes (often or sometimes)77 (7.9)37 (5.4) 0.67 [0.44–1.00], p = 0.049 not relevant(n = 1664)No (RG)900 (92.1)650 (94.6)–Alcohol use disorderYes232 (25.7)142 (22.1)0.82 [0.65–1.04], p = 0.109–(n = 1546)No (RG)672 (74.3)500 (77.9)––At risk transfusion (before 1990)Yes11 (1.2)15 (2.2)1.97 [0.90–4.30], p = 0.092–(n = 1632)No (RG)948 (98.8)658 (97.8)––Transactional sex (last intercourse)Yes46 (5.7)47 (8.2)1.48 [0.97–2.25], p = 0.070–(n = 1384)No (RG)763 (94.3)528 (91.8)––Age at first intercourse < 15 YOYes272 (32.3)164 (28.6)0.84 [0.67–1.06], p = 0.145–(n = 1416)No (RG)571 (67.7)409 (71.4)––CI: confidence interval, HBV: hepatitis B virus, IQR: inter quartile range, OR: odds ratio;RG: reference group; P-values in bold are statistically significant; All selected known or potential risk factors with a p-value < 0.15 are presented in this table; *Ndjukatongo, Aluku, Pamaka, Saramaka; †Wayana, Teko, Trio, Apalai. Logistic regression models for risk factors of HBV exposure along the Maroni. CI: confidence interval, HBV: hepatitis B virus, IQR: inter quartile range, OR: odds ratio;RG: reference group; P-values in bold are statistically significant; All selected known or potential risk factors with a p-value < 0.15 are presented in this table; *Ndjukatongo, Aluku, Pamaka, Saramaka; †Wayana, Teko, Trio, Apalai. In multivariable analysis, older age was significantly associated with HIV infection (per 10-year increase aOR:1.64, 95%CI:1.11–2.44), and participants of other ethnic groups (aOR:3.81, 95%: CI 1.14–12.26); compared to Amerindian and Maroon ethnic groups had significantly higher odds of having an HIV infection (p = 0.020; Table 4). No other determinants were associated with an HIV infection. 10.1371/journal.pone.0344187.t004Table 4Logistic regression models for risk factors HIV infection along the Maroni.Known or suspected risk factorsHIV-positiveHIV-negativeBivariable modelsMultivariable model(N analyzed in bivariable analyses)N (%) or median [IQR]OR [95%CI], p-valueaOR [95%CI], p-value For HIV Infection (n = 2150) (n = 12) (n = 2138) (n = 2087) Age (n = 2095)(per 10-year increase)48 [44-61]42 [32-52] 1.52 [1.06–2.18], p = 0.019 1.64 [1.11–2.44], p = 0.01 SexMale6 (50.0)936 (43.8)1.28 [0.43–3.81], p = 0.6571.09 [0.35–3.36], p = 0.881(n = 2147)Female (RG)6 (50.0)1199 (56.2) – – Mother tongue*Portuguese and other5 (41.7)404 (19.0) 3.13 [1.04–9.48], p = 0.043 3.81 [1.14–12.26], p = 0.020 (n = 2144)Amerindian† or Maroon‡7 (58.3)1728 (81.0)– – TattoosYes0 (0.0)516 (24.3)0.12 [0.01–2.11], p = 0.149–(n = 2133)No (RG)12 (100)1605 (75.7)–PiercingYes5 (41.7)726 (34.2)0.38 [0.13–1.15], p = 0.087–(n = 2135)No (RG)7 (58.3)1397 (65.8)–Transactional sex (LI)Yes2 (22.2)131 (7.4)4.17 [0.98–17.73], p = 0.053–(n = 1786)No (RG)7 (77.8)1646 (92.6)–Age at first intercourse < 14 YOYes4 (44.4)321 (17.5)3.86 [1.10–13.53], p = 0.034>20% missing data(n = 1416)No (RG)5 (55.6)1518 (82.5)––CI: confidence interval, HBV: hepatitis B virus, HIV: human immunodeficiency virus, IQR: inter quartile range, OR: odds ratio, LI: last intercourse; P-values in bold are statistically significant; Age and sex were forced into the final multivariable model; *Mother tongue groups with very small sample sizes or no HIV cases were combined to avoid sparse-data issues; †Wayana, Teko, Trio, Apalai; ‡Ndjukatongo, Aluku, Pamaka, Saramaka;. Logistic regression models for risk factors HIV infection along the Maroni. CI: confidence interval, HBV: hepatitis B virus, HIV: human immunodeficiency virus, IQR: inter quartile range, OR: odds ratio, LI: last intercourse; P-values in bold are statistically significant; Age and sex were forced into the final multivariable model; *Mother tongue groups with very small sample sizes or no HIV cases were combined to avoid sparse-data issues; †Wayana, Teko, Trio, Apalai; ‡Ndjukatongo, Aluku, Pamaka, Saramaka;. With only five participants infected with HCV, we did not perform statistical analysis to assess risk factors for HCV infection in this population. However, HCV-infected participants were mostly male (n = 4 or 80%) and older (59.0 ± 7.8 years old) than our global study population (43.7% male and 42.8 ± 14.4 years old). Furthermore, we noted an overrepresentation of drug use (n = 3 or 60%), injection drug use (n = 2 or 50%), and dental care outside of official care facility (n = 3 or 60%) among our HCV-positive participants compared to the global population study (8.8%, 0.7%, and 12.3% respectively). KAP-B regarding viral hepatitis Knowledge and awareness about viral hepatitis were very low (S6 Table); approximately one in three participants had heard about HBV and one in five participants about HCV. Of those who had heard about it, one-third believed mosquito bites to play a role in transmission. Approximately half correctly cited mother-to-child transmission and IDU as risk factors for viral hepatitis, and over half correctly identified unprotected sex as a risk factor. Self-reported testing rates were very low: 11.8% for HBV and 8.3% for HCV. Among 2116 responders, 255 (12.1%) said they were vaccinated against HBV. Discussion This study among adults living along the remote and rural French Guiana-Suriname border shows an adjusted HBsAg, resolved HBV infection, HCV, and HIV seroprevalence of 2.08% (95%CI: 1.49–2.66), 25.06% (95%CI: 20.89–29.24), 0.13% (95%CI: 0.00–0.27) and 0.65% (95%CI: 0.0–1.40) respectively. There were no HDV infections. Prevalence of all HBV, HCV and HIV were comparable, although somewhat lower, to the prevalence found in the urban areas of FG and Suriname; in the urban areas, HBsAg was 3% and 3.2% respectively in FG and Suriname [11], anti-HBc was 33% in pregnant women in Saint-Laurent-du-Maroni in FG [25] and 24.5% (95%CI: 22.7–26.4%) in Suriname [11], anti-HCV seropositivity was 0.67% in Cayenne [26] and 1.0% (95%CI: 0.6–1.58) in the (Emergency Department) ED population in Paramaribo, Suriname [12], however, prevalence was highest in people of Javanese descent, of which there were only fifteen in this study. In fact, in the ED study, in Afro-Surinamese participants, HCV prevalence was an estimated 0.69% (95%CI: 0.17–2.91). HIV prevalence in the urban areas was 1.18%−1.35% in FG [2] and 1.6% (95%CI: 1.3–1.9) HIV seropositivity overall [3]. Older age, male sex, Maroon or other ethnicity (compared to Amerindians) and lower education level were all significantly associated with HBV exposure in this transborder population. Interestingly, apart from male sex, the same determinants: older age, Maroon ethnicity and lower education were found to be associated with HBV exposure in the ED population in the urban region Paramaribo, suggesting similar HBV prevalence and modes of transmission throughout Suriname. Similarly, HBV was also more often seen in males in the urban areas of French Guiana, and within a subgroup of pregnant women, HBV was more often seen in Asians, Haitians and Maroons [27]. The trend between older age and HBV exposure has also been observed in other Latin American countries [28]. This association is likely due to cumulative exposure to HBV risk factors over time. Furthermore, the relatively high rate of resolved HBV infection identified in this study suggests that the majority of participants were likely infected later in life. Specifically, the ratio of HBsAg prevalence (2.08%) to resolved HBV infection (25.06%) aligns with the expected 5–10% chronic HBV persistence rate following adult-acquired infections, supporting the interpretation that HBV acquisition predominantly occurred during adulthood rather than through early-life transmission. Males had significantly higher HBV exposure compared to females. This has been seen in other countries, including neighboring Brazil [28], with increased sexual risk behavior identified as possible determinant. In our study, polygamy was a significant determinant in bivariable analysis; however due to the large proportion of missing data, it could not be included in the multivariable model. However, in the male subgroup analysis, this determinant was only borderline significant. Interestingly, in our study, none of the other potential sexual risk factors, including self-reported STI’s, condomless sex, were associated with HBV or HIV. This finding should be interpreted with caution, as self-reporting of STIs is notoriously low, as the majority of people who have had an STI are in fact asymptomatic [29] and STI-associated stigma may have led to underreporting of STIs. Likewise, use of condom at last sexual encounter might also have been affected by this same social desirability bias [30], leading to a potential underestimation of this risk. These findings highlight the importance of tailoring awareness and testing strategies to include men. Multiple sex partners or polygamy might also explain why Maroon and other ethnic groups demonstrated a significantly higher HBV exposure proportion compared to Amerindians. A previous KAP-B study along the Maroni also showed significant differences between the Maroon and Amerindian population regarding multiple sex partners [15]. Moreover, polygamy within the Maroon ethnic group is culturally accepted [31]. Elsewhere, ethnic disparities regarding HBV, and health care in general, are also well documented. In the US, for example, HBV prevalence among non-Hispanic blacks is significantly higher than other ethnic groups. Moreover, African-Americans and Mexican-Americans had significantly lower vaccine coverage [32]. Similarly, in Suriname, afro-Surinamese are disproportionately affected by HIV compared to other ethnic groups. Approximately 70% of HIV infections occur among Afro-Surinamese descent [33], although they comprise only 38% of the population. Again, emphasizing safe sex practices is therefore crucial to reducing transmission of both HIV and HBV, as well as addressing these disparities. Interestingly, Amerindian participants in our study were more often vaccinated, which of course resulted in less HBV infection, and might be the primary reason for the disparity in HBV prevalence among the different ethnic groups. However, Maroon or other ethnic groups have higher odds of HBV exposure, underscoring the need for targeted HBV awareness campaigns, and also assessing whether catch-up vaccinations are warranted. Remaining on the topic of awareness, there was a notable association between HBV exposure and lower educational level, highlighting the importance of targeted educational programs. This finding is consistent with studies conducted in comparable low- and middle- income settings [34]. Increasing knowledge and awareness of viral hepatitis is recommended as only one-third of the participants in our study had heard about HBV and one-fifth about HCV, with overall poor to average knowledge regarding transmission routes. The latter is in contrast with a previous KAP-B study on HIV among Maroni boatmen, where over 90% correctly identified unprotected sex as a transmission risk factor for HIV, reflecting the effect of the numerous preventive efforts on HIV in FG and Suriname [15,35,36]. Unfortunately, at the time, these initiatives focused exclusively on HIV and did not address viral hepatitis, or other STIs. Inclusive and tailored educational initiatives should be implemented to improve awareness in all populations, including guidance on safe sex practices and prevention of HBV as well as other sexually transmitted or blood-borne infections. Given the low HCV prevalence, statistical analyses were not possible; however, notable determinants among anti-HCV seropositive participants included male sex, and older age – two determinants also seen in the ED population in Paramaribo [12] –, as well as injection drug use, and dental care in non-regulated settings. These factors warrant further investigation, and HCV screening should be considered for individuals exposed to such risks. Regarding HIV, only older age and non-autochtonous ethnic groups were significantly associated with infection. This pattern may be explained by the delayed but rapid rise of HIV prevalence in pregnant women in the 1990s on the Maroni river [37], after which numerous HIV awareness and testing programs were introduced throughout the region. Presumably, these programs primarily targeted the local tribal and Amerindian population in this hard-to-reach area. At the same time, access to testing and treatment in these remote regions are more limited for hard-to-serve populations, particularly the non-autochthonous groups who are more often undocumented [38]. Both these disparities might explain the higher prevalence among non-autochthonous populations. To achieve elimination of both viral hepatitis and HIV, it is essential that all populations, including marginalized and undocumented groups, are reached through tailored programs ensuring equitable access to testing, prevention, and treatment services. Hopefully with increased awareness and knowledge of HIV and its risk factors, access to PrEP and condoms, prevalence of HIV will decrease [39]. We found no associations between hypothesized cultural risk factors – bugrus, vaginal steam baths, therapeutic koti scarifications-, tattoos, or piercings, and viral hepatitis or HIV infection in this study. While bugrus were expected to increase bloodborne infection risk in men during insertion [40], and STI risk in women, through mechanisms such as mucosal micro-abrasions and higher rates of condom rupture [41], we did not observe any significant association. However, there were a significant number of missing responses regarding bugrus, especially among female participants. Another hypothesized cultural practice – vaginal steam baths which were very often practiced – was not associated with the viral infections tested. Interestingly, despite the sensitive question, 94% of women responded to this question. Similarly, kotis were not associated with HBV exposure, although this association was seen in East Africa [42]. Contrary to expectations, tattoos and piercings – regardless of whether they were performed in regulated or non-regulated settings – were also not associated with any of the infections examined. Overall, despite the presence of numerous transmission risk factors, these data are in alignment with the general assumptions that with less dense sexual networks, HIV or HBV prevalence in rural areas generally tend to be lower than in urban areas [43]. A notable exception is the somewhat higher, although non-significant, HBsAg and HIV prevalence we found in the Brazilian population (mostly gold miners or garimpeiros), presumably reflecting the generally greater risk for STIs [44,45] in this highly precarious and mobile population where turnover is fast, transactional sex is frequent [45] and access to health care is challenging [7]. The non-existent HDV seropositivity we observed is noteworthy given the relatively high prevalence found in other studies conducted in South America. To our knowledge, this is the first hepatitis D seroprevalence study in Suriname. In FG, we are aware of one study on HDV infections, which showed no HDV coinfections in 19 HBsAg-seropositive patients out of 416 gold-miners from Brazil living along the FG Suriname border [44]. In South America, anti-HDV seropositivity has shown to vary significantly between and within areas, with an estimated pooled HDV prevalence of 22.4% among all hepatitis B carriers, 22.2% in Native indigenous communities and 32.1% in the Amazon basin, even though the most recent studies indicate a lower seroprevalence around 7% [46]. Further testing for HDV in the more urban areas in FG and Suriname would be of interest to verify whether our finding is only confined to the rural areas. Another interesting finding in this study, was the low HBV vaccination coverage, although significantly higher than the 6.0% found in a previous study in Suriname in 2012 [11]. As only 23.5% had effective protection due to vaccination in our study, efforts to increase the vaccination rate are an important message for the health authorities, specifically for people born before 2005, since universal hepatitis B vaccination program was put into place for all newborns in Suriname in 2005 and in FG since 1994 [47]. Nonetheless, vaccination rates in Suriname’s hard-to-reach interior are far lower than the urban areas [48]. In FG, children’s HBV vaccination coverage is increasing but is still low in adults, especially on the Maroni [4]. This lower vaccination coverage level along the Maroni is not fully understood, but thought to be mainly caused by logistical constraints of these remote territories as well as vaccine hesitancy due to misinformation in FG [49] and Suriname [48]. The originality and strength of our study is that, whereas most published data on viral hepatitis and HIV in the region concern urban areas, our study focused on a rural transborder area. By using DBS for laboratory analysis, we ensured broad inclusion and testing of participants in even the very remote areas. Nevertheless, there are several limitations. First, although we called on cultural mediators to ensure participant comprehension and participation, refusals to answer certain questions were common. In addition, self-reported data may be affected by social desirability bias, which could have influenced the accuracy of participants’ responses. Second, random sampling was not feasible in the context of hundreds of scattered small informal villages in the Amazon forest. In fact, the sampling was expanded per special request of the community leaders. This non-random sampling, may have introduced selection bias, potentially favoring the inclusion of individuals who are more integrated into the community, thereby limiting the participation for more marginalized persons. We thus attempted to correct prevalence estimates through sampling weights, however, this cannot fully remove the risk of bias. Third, some people living with HIV, HBV, or HCV, and aware of their infection, potentially did not participate in the study, which would have led to an underestimation of the true prevalence. Indeed, 6% opted out for HIV-testing and some of them did so declaring they were HIV-positive. However, the opt-out policy presumably led to a high participation rate; the HBV and HCV prevalence is however, likely more accurate than for HIV. Despite the opt-out, we believe that due to the large sample size, the HIV prevalence estimates are robust. Fourth, although the use of DBS was a strength and allowed testing of more than 2,000 participants, it also introduced methodological constraints. The serological assays were originally validated for serum rather than DBS eluates, and despite adjusting cutoffs to account for potential matrix effects, residual differences in analyte recovery and assay performance may still have resulted in some degree of misclassification. Despite this, recent meta-analyses highlighted the exceptional diagnostic accuracy of HBsAg and HCV serology, as well as molecular analyses conducted using DBS, reporting over 98% sensitivity and specificity [50,51]. Fifth, as low level HBV DNA is difficult to detect using DBS, we were unable to collect data on occult HBV infection – defined as presence of HBV DNA in the liver with detectable or undetectable HBV DNA levels in serum, in individuals who are HBsAg seronegative [52]. In terms of public health, and prevention of HBV transmission, this aspect warrants further research. Lastly, HIV results should be interpreted with caution, due to the wide confidence intervals observed, which reflect the small number of positive cases. The number of positives for HBV, HCV, and HIV were small and our analyses on determinants may therefore have suffered from low statistical power, and more data are needed. Conclusion This is the first, large scale viral hepatitis and HIV prevalence study in hard-to-serve populations along the French Guiana-Suriname border, which showed that the prevalence of these viral infections was somewhat, though not significantly, lower than in urban areas, but still substantial. This study, coupled with the limited knowledge surrounding these viral infections, underscores the need for more accessible and integrated healthcare systems for all populations, including marginalized, undocumented and key populations. Regular screening initiatives, accompanied by awareness campaigns, are crucial for promoting prevention methods such as catch-up HBV vaccination and PrEP. Furthermore, the provision of treatment and care for those already infected remains essential. Lastly, the findings from this study demonstrated that certain cultural practices – such as bugrus, vaginal steam baths and kotis, – although prevalent, were not associated with HBV, HCV, or HIV infections. Supporting information Supplementary tables. This file contains the following tables: S1 Table. Number of participants and majority ethnicity per site and per country in the MaHeVi study. S2 Table. Serological and molecular markers of HBV, HCV, HDV, and HIV infection on dried blood spots in the MaHeVi study. Abbreviations: Ab: antibody, Ag: antigen, HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, HIV: human immunodeficiency virus, tot Ig Delta: HDV antibodies; ‡ 5/52 positive were later tested on whole blood samples and confirmed negative; † 3/17 positive were later tested on whole blood samples and confirmed negative; * 3/9 equivocal anti-HCV Ab were later tested on whole blood samples and confirmed negative. S3 Table. Hepatitis B infection profile according to serological markers in the MaHeVi study. Abbreviations: HBc-Ab: hepatitis B core antibodies, HBs Ab: hepatitis surface antibodies HBsAg: hepatitis B surface antigen, HBV: hepatitis B virus. S4 Table. Sub-group analyses for HBV-exposure determinants for men and women separately. Abbreviations: CI: confidence interval, HBV: hepatitis B virus, IQR: inter quartile range, OR: odds ratio, LI: last intercourse, RG: reference group; *Ndjukatongo, Aluku, Pamaka, Saramaka; †Wayana, Teko, Trio, Apalai; All selected known or potential risk factors with a p-value < 0.15 are presented in this table; Variables with more than 20% missing data were excluded for the multivariable models (polygamous relationship); Variables with counterintuitive OR (protective effect of piercings and toothbrush sharing) were not included in the multivariate models; ‡ Mother tongue was forced into the multivariable model at first but didn’t change the age OR values; Observations with equivocal DBS results were not included in the analyses; P-values in bold are statistically significant. S5 Table. Sub-group analyses for HBV-exposure determinants for language communities separately (Amerindian, Maroon, Others). Abbreviations: CI: confidence interval, HBV: hepatitis B virus, IQR: inter quartile range, OR: odds ratio, LI: last intercourse, RG: reference group; *Participants declaring their mother tongue as either Ndjukatongo, Aluku, Pamaka or Saramaka; †Participants declaring their mother tongue as either Wayana, Teko, Trio, Apalai; All selected known or potential risk factors with a p-value < 0.15 are presented in this table; Variables with more than 20% missing data were excluded for the multivariable models (polygamous relationship, bugrus and transactional sex); Variables with counterintuitive OR (protective effect of piercings and toothbrush sharing) were not included in the multivariate models; ‡ Sex was forced into the multivariable model at first but didn’t change the Age OR values; Observations with equivocal DBS results were not included in the analyses; P-values in bold are statistically significant. S6 Table. Knowledge, attitudes, practices, and beliefs study results on HBV and HCV in the MaHeVi study. Abbreviations: HBV: hepatitis B virus; HCV: hepatitis C virus, HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; Answers on the modes of transmission of viral hepatitis were only considered if the participant declared having already heard of this viral hepatitis. (XLSX) Inclusivity in global research questionnaire (DOCX) 13 Aug 2025 -->PONE-D-25-23462-->-->A cross-border seroprevalence study on HBV, HCV, HDV and HIV in remote Amazonian communities on the border between French Guiana and Suriname-->-->PLOS ONE Dear Dr. Schaub, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 27 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Getu Girmay Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript. 3. We note that Figure 1 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (a) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (b) remove the figures from your submission: a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].” b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only. The following resources for replacing copyrighted map figures may be helpful: USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/ The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/ Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/ Landsat: http://landsat.visibleearth.nasa.gov/ USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/# Natural Earth (public domain): http://www.naturalearthdata.com/ 4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Partly ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The authors performed a seroprevelance study of hepatitis B, C and D and HIV, in the border between French Guiana and Suriname. Some concerns need to be addressed before acceptance of this manuscript 1. The results show an apparent low prevalence of HBsAg in the Amerindian ethnic group. This may be due to the low number of individuals from this ethnic group, in addition to the age of the participants: higher HBsAg prevalence may have been found at lower ages. It would be interesting to include in Table 1 anti-HBc prevalence and perform the analysis of risk factors for HBV according to this marker and not (only) to HBsAg. The presence of anti-HBc is only presented in a supplemental table. 2. Additional Table 2. Footnote is incomplete: some superscript symbols (*, for example), are not explained in the footnote. 3. According to Additional Table 2, the prevalence of anti-HBc is indeed quite high, not reflected in the prevalence of HBsAg. It is important to analyze this (high) prevalence of exposure in each population group and to correlate with the risk factors. This is even more important than the correlation with HBsAg. 4. Did the authors consider to analyze occult HBV infection in at least part of the anti-HBc positive samples? 5. Another concern is the presence of false positive results in these population groups. In rural populations, the presence of polyclonal activation might be frequent, due for example to parasitic infections. This may lead to false positive antibody results, less expected for anti-HBc, which is an inhibition assay (then more specific) but relatively frequent with anti-HCV in some population groups (see for example Rogers KJ, et al., J Clin Lab Anal. 2023 Apr;37(7):e24887. doi: 10.1002/jcla.24887. Epub 2023 Apr 27. The presence of only 20% of viremic samples among the anti-HCV positive ones suggest that some false positive results may have occurred. The authors may consider a second testing with another commercial assay or applying a more stringent criteria of positivity based on signal to cutoff ratio. 6. Discussion. The comparison between anti-HBc prevalence should be included, and limitation on anti-HCV testing. Reviewer #2: 1. Could you clarify the rationale behind offering an "opt-out" for HIV testing, rather than an "opt-in"? 2. Did the demographic characteristics of the 6% who opted out differ from those who consented, and how might this have affected the final reported HIV prevalence? 3. How was the question about "transactional sex" phrased by the cultural mediators to distinguish it from formally declared "sex work"? Understanding this operational definition is crucial for interpreting its significance as a risk factor. 4. The supporting information notes that some initial positive results from Dried Blood Spots were later found to be negative on whole blood samples. Were the final prevalence figures and risk factor analyses based on the initial screening results or only on the confirmed cases? 5. Could you specify the source and year of the census data used for the post-stratification weighting? Given the high mobility in this border region, how accurate and current is this data considered to be? 6. The literature review is well-focused on the Guiana Shield and South America. However, the discussion could be strengthened by contextualizing the findings with recent literature from other low- and middle-income regions facing similar public health challenges. For example, comparing prevalence rates in key populations (like pregnant women) or vaccination barriers could highlight universal themes. The following recent articles, while geographically distant, explore relevant topics and could be considered for inclusion: o Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women attending a tertiary care hospital in Mogadishu, Somalia, 2017–2021 (DOI: 10.1186/s12879-025-11268-9) o Prevalence and associated factors for hepatitis B infection among pregnant women attending antenatal clinic at SOS Hospital in Mogadishu, Somalia (DOI: 10.3389/fgwh.2024.1279088) o Uptake of hepatitis B vaccination and associated factors among health sciences students, Mogadishu, Somalia (DOI: 10.3389/fpubh.2023.1203519) Reviewer #3: My comments have been attached as a Word document. While the paper presents data with great global health importance, it needs major revision. Specific comments for each section of the paper have been attached. Particularly, the abstract, methods, results, and conclusions sections need more improvement. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. Submitted filename: Comments.docx Submitted filename: To PLOSE ONE.docx 27 Nov 2025 Authors’ Revisions and Responses to Reviewers’ Comments We thank the editor and reviewers for their thoughtful and constructive comments. We have carefully revised the manuscript accordingly. Below, we provide a point-by-point response to each comment. Before addressing these comments, we would first like to highlight several changes made to the manuscript that are indirectly related to the reviewer’s comments and important to make following a careful review of the biological results and, in particular, the thresholds used to interpret these results. We had initially set lower thresholds for the detection of HBsAg and anti-HCV antibodies in order to account for the potential lack of sensitivity of DBS compared to serum from venous blood and to minimize the risk of false negatives, which would have been detrimental to the interests of the participants. However, for HBsAg, the results that we were subsequently able to verify on venous blood were consistent with the thresholds provided by the manufacturer for the LIAISON® XL Murex HBsAg Quant kit (DiaSorin). We have therefore considered the thresholds for HBsAg as follows, in accordance with the recommendations of the manufacturers of the kits used: reactive (positive) result if index value ≥1.00, non-reactive (negative) result if index value <1.00. Accordingly, for anti-HCV antibodies, we revised the initially broader cutoffs to bring them closer to the manufacturer’s recommendations for the LIAISON® XL MUREX HCV Ab assay (DiaSorin): non-reactive if S/CO <0.80, equivocal if 0.80–1.00, and reactive if ≥1.00. However, because the assay was performed on DBS eluates, we retained a slightly broader equivocal range, classifying results between >0.20 and <1.00 as equivocal. This has changed the number of participants in the “HBsAg+” and “HCV+” columns in Tables 1 and 2. We have therefore modified the corresponding numbers in the manuscript text as well as in Additional Tables 2 and 3 (where the modified elements are highlighted in yellow). Overall, we reviewed all serological cutoff values used in the study and clarified the laboratory procedures in the revised manuscript, specifically in the Materials and Methods section. In addition, detailed information on assay thresholds has been added to Supplementary Table 2. Reviewer #1: The authors performed a seroprevalence study of hepatitis B, C and D and HIV, in the border between French Guiana and Suriname. Some concerns need to be addressed before acceptance of this manuscript. We sincerely thank reviewer #1 for their insightful comments and questions, which we will attempt to address below point by point. 1. The results show an apparent low prevalence of HBsAg in the Amerindian ethnic group. This may be due to the low number of individuals from this ethnic group, in addition to the age of the participants: higher HBsAg prevalence may have been found at lower ages. It would be interesting to include in Table 1 anti-HBc prevalence and perform the analysis of risk factors for HBV according to this marker and not (only) to HBsAg. The presence of anti-HBc is only presented in a supplemental table. Notably, the vaccination uptake in the Amerindian group was significantly higher than in the non-Amerindian group. Consequently, in the first paragraph of the results, we removed results that were redundant with Table 1 and replaced them with results comparing the sociodemographic characteristics (age, sex, education) of vaccinated and unvaccinated participants. We agree with the reviewer to include risk factors for HBV exposure based on anti-HBc seropositivity (regardless of HBsAg status) and have added these description to Tables 1 and 2. As the reviewer correctly noted, exploring HBV infection risk factors only in patients with acute or chronic infection (based on HBsAg positivity) was not the most appropriate, as it does not consider infected individuals who have cleared the infection - a significant proportion of those exposed to the virus, particularly adults [Hepatitis B WHO fact sheets]. We therefore revised the HBV risk factor analyses, initially performed only on individuals with positive HBsAg, with an analysis comparing individuals who were HBV exposed to HBV susceptible individuals, which is not only more relevant from a disease history perspective, but also allows us to present much more robust models, due to the larger number of events. 2. Additional Table 2. Footnote is incomplete: some superscript symbols (*, for example), are not explained in the footnote. We thank the reviewer for their vigilance. We have completed the footnotes for Additional Table 2, corrected “HBe Ab”, which was a typo, to “HBe Ag”, and made changes to the numbers in some cells (highlighted in yellow) following the redefinition of certain thresholds as explained at the beginning of this document: - we initially indicated “‡ 5/52 positive were later tested on whole blood samples and confirmed negative”, but we removed this sentence because these 5 participants had in fact negative HBs Ag with the new threshold definition we describe at the beginning of the document, and replaced with the following precision “‡ 7/46 positive were later tested on whole blood samples and confirmed positive” - “† 3/17 [Anti-HCV Ab] positive were later tested on whole blood samples and confirmed negative” was changed to “4 [Anti-HCV Ab] positives were not retested and 1 was already known and treated” - “* 3/9 equivocal anti-HCV Ab were later tested on whole blood samples and confirmed negative” was changed to “* 4/12 equivocal anti-HCV Ab were later tested on whole blood samples and confirmed negative”. 3. According to Additional Table 2, the prevalence of anti-HBc is indeed quite high, not reflected in the prevalence of HBsAg. It is important to analyze this (high) prevalence of exposure in each population group and to correlate with the risk factors. This is even more important than the correlation with HBsAg. Please see our response to comment 1. We agree with the reviewer and, in addition to modifying the analysis of HBV infection risk factors to include not only HBsAg-positive participants but also anti-HBc-positive participants, we also performed subgroup analyses by sex and by language community, the detailed results of which have been added in Additional Tables 4 and 5, respectively. 4. Did the authors consider to analyze occult HBV infection in at least part of the anti-HBc positive samples? This is a very valid point. However, occult hepatitis B infection (OBI) is defined by the persistence of HBV DNA in the absence of detectable HBsAg. By nature, the viral load is extremely low, usually below 200 IU/mL, and often at the level of 10–50 IU/mL, sometimes detectable only intermittently with highly sensitive PCR assays. Given that the threshold for detection of HBV DNA assays performed on dried blood spots (DBS) is approximately 50-fold higher than that of plasma-based molecular methods, the probability of detecting such low and fluctuating levels of viremia becomes negligible. As a result, DBS testing is not appropriate for the diagnosis or monitoring of OBI, since it would systematically underestimate the true prevalence, Therefore, HBV DNA testing on DBS cannot be recommended for the evaluation of occult hepatitis B, as it lacks the analytical sensitivity required to capture the very low viral loads that define this condition. Furthermore, we know that anti-HBs is less sensitive on DBS, therefore per WHO recommendations we have included only anti-HB-core positive results as part of resolved HBV infections. It is not appropriate for diagnosis or monitoring of occult HBV infections (OBI; defined by persistence of HBV DNA in the absence of HBsAg) since HBV loads in case of OBI are generally extremely low, and not detected by molecular DBS testing. Hence, we may have missed OBI. However, we have added OBI as a limitation to the manuscript: “Fifth, as low level HBV DNA is difficult to detect using DBS, we were unable to collect data on occult HBV infection - defined as presence of HBV DNA in the liver with detectable or undetectable HBV DNA levels in serum, in individuals who are HBsAg seronegative) (EASL 2017 Guidelines). In terms of public health, and prevention of HBV transmission, this aspect warrants further research”. 5. Another concern is the presence of false positive results in these population groups. In rural populations, the presence of polyclonal activation might be frequent, due for example to parasitic infections. This may lead to false positive antibody results, less expected for anti-HBc, which is an inhibition assay (then more specific) but relatively frequent with anti-HCV in some population groups (see for example Rogers KJ, et al., J Clin Lab Anal. 2023 Apr;37(7):e24887. doi: 10.1002/jcla.24887. Epub 2023 Apr 27). The presence of only 20% of viremic samples among the anti-HCV positive ones suggest that some false positive results may have occurred. The authors may consider a second testing with another commercial assay or applying a more stringent criteria of positivity based on signal to cutoff ratio. We thank reviewer 1 for this comment, which lead us to carefully review our biological results and, in particular, the thresholds used to interpret these results. As indicated in the introduction to this letter, we had initially set lower thresholds for the detection of anti-HCV antibodies in order to account for the lower sensitivity of DBS compared to serum from venous blood. We were subsequently able to verify on venous blood a few equivocal anti-HCV Ab participant’s result, and they were all confirmed negative. For anti-HCV Ab, we revised the initially broader cutoffs to bring them closer to those indicated by the manufacturer of the LIAISON® XL MUREX HCV Ab kit (DiaSorin): non-reactive (negative) if S/CO value <0.80; equivocal if S/CO value [0.80-1.00], reactive (positive) if S/CO value ≥1.00. After re analyzing the results, we identified five anti HCV positive cases, four of whom also tested positive for HCV RNA which is more consistent with expected HCV serology. 6. Discussion. The comparison between anti-HBc prevalence should be included, and limitation on anti-HCV testing. We have now added the discussion on anti-HBcore seropositivy. Due to the anti-HCV results being in line with expected HCV serology, we no longer view the anti-HCV testing using DBS as a limitation, and did not add this. Reviewer #2: We would like to thank the reviewer for their insightful comments and questions, which we will attempt to address below point by point. 1. Could you clarify the rationale behind offering an "opt-out" for HIV testing, rather than an "opt-in"? We chose opt-out regimens rather than opt-in for HIV testing, because opt-out can substantially increase HIV testing compared to opt-in schemes (Montoy JCC, Dow WH, Kaplan BC. Patient choice in opt-in, active choice, and opt-out HIV screening: randomized clinical trial. BMJ. 2016 Jan 19;352:h6895; doi: https://doi.org/10.1136/bmj.h6895). We have added this clarification and the associated reference to the manuscript by replacing the following sentence: “This opt-out was offered because of our perception that HIV testing might be a factor in not participating.” with “We chose the opt-out option for HIV testing based on data indicating this may increase test acceptance rate [ref].” 2. Did the demographic characteristics of the 6% who opted out differ from those who consented, and how might this have affected the final reported HIV prevalence? We compared the demographic characteristics of the 134 participants who refused the HIV test with the 2152 participants who accepted it. There were no differences in sex, age, professional activity, but there were differences for the following characteristics: - country of birth: there were less participants who refused HIV testing among those born in Suriname (4.2%) compared to participants born in French Guiana (8.8%) or in another country (5.3%), p=0.002. - country of residence: there were less participants who refused HIV testing among those living in Suriname (3.1%) compared to participants living in French Guiana (7.5%) or in another country (6.7%), p=0.002. - school level: HIV testing refusal rate in participants who have been to high school was higher (11.2%) compared to participants who have either never been to school / primary / middle school and higher education, with HIV testing refusal rates of 4.1, 3.8, 6.0 and 6.6%, respectively, p<0.0001. We have included the following sentence to the manuscript in the results section: - Six percent (n=134) participants opted out HIV-testing. There were significant differences in country of birth and residence, and educational level between participants who opted out for HIV testing compared to those that did not. There were no differences in sex, age, work, or other determinants. And in the discussion/limitation section: - Indeed, 6% opted out for HIV-testing and some of them did so declaring they were HIV-positive. However, the opt-out policy presumably led to a high participation rate; the HBV and HCV prevalence is however, likely more accurate than for HIV. Despite the opt-out, we believe that due to the large sample size, the HIV prevalence estimates are robust. 3. How was the question about "transactional sex" phrased by the cultural mediators to distinguish it from formally declared "sex work"? Understanding this operational definition is crucial for interpreting its significance as a risk factor. The specific question that the mediators asked was “The last time you had sex, did you pay your partner or were you paid by your partner?”. This precision appears in our manuscript as the following footnote in Table 2: “Transactional sex was defined as having paid for or having been paid in exchange for sex”. This formulation implied that we were asking specifically about money and not gifts, compared to what has been done by other authors, for example Ranganathan et al. in young women in rural South Africa, where they distinguished receiving money and gifts in 2 separate questions. In our study, because of the design (same questionnaire for both women and men) and setting, we preferred to use a single succinct question, so as not to overload the questionnaire, which could have slowed down inclusions and discouraged some people from participating. Moreover, this questionnaire was developed based on an extensive preliminary assessment in the communities, including focus group discussions and interviews with key individuals. We believe that the questionnaire was therefore tailored to the population. However, distinguishing sex work and transactional sex, as well as the nuance between money and gifts is interesting, and it might be worthwhile to explore these issues in a more focused project on the Maroni river, especially among girls and young women. 4. The supporting information notes that some initial positive results from Dried Blood Spots were later found to be negative on whole blood samples. Were the final prevalence figures and risk factor analyses based on the initial screening results or only on the confirmed cases? As indicated in the introduction to this letter, we had initially set lower thresholds for the detection of HBsAg and anti-HCV antibodies than the thresholds provided by the manufacturer for the LIAISON® XL Murex HBsAg Quant kit (DiaSorin) in order to account for the potential lack of sensitivity of DBS compared to serum from venous blood and to minimize the risk of false negatives, which would have been detrimental to the interests of the participants. However, for HBsAg, the results that we were subsequently able to verify on venous blood were consistent with the thresholds provided by DiaSorin. We have therefore considered the thresholds for HBsAg as follows, in accordance with the recommendations of the manufacturers of the kits used: reactive (positive) result if index value ≥1.00, non-reactive (negative) result if index value <1.00. For anti-HCV Ab, the manufacturer of the LIAISON® XL MUREX HCV Ab kit (DiaSorin) indicate the following thresholds: non-reactive (negative) if S/CO value <0.80; equivocal if S/CO value Submitted filename: 2025.11.21 Rebuttal letter.docx 9 Jan 2026 -->PONE-D-25-23462R1-->-->A cross-border seroprevalence study on HBV, HCV, HDV and HIV in remote Amazonian communities on the border between French Guiana and Suriname-->-->PLOS One Dear Dr. Schaub, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that minor revision is mandatory and it does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 23 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. -->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Getu Girmay Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #3: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #3: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #3: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #3: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The authors addressed satisfactorily the concerns. All the concerns were responded point by point. Reviewer #3: Dear Authors, thank you for carefully addressing my comments. Most of my comments have been addressed. However, the paper still lacks a separate section from the conclusion, both in the abstract and at the end of the discussion. Conclusion should stand alone as heading in the abstract and body part. If the authors have made subordinate paragraphs of the conclusions section in the discussion, it has to stand independently for readers. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 14 Jan 2026 Authors’ Revisions and Responses to Reviewers’ Comments First revision: We thank the editor and reviewers for their thoughtful and constructive comments. We have carefully revised the manuscript accordingly. Below, we provide a point-by-point response to each comment. Before addressing these comments, we would first like to highlight several changes made to the manuscript that are indirectly related to the reviewer’s comments and important to make following a careful review of the biological results and, in particular, the thresholds used to interpret these results. We had initially set lower thresholds for the detection of HBsAg and anti-HCV antibodies in order to account for the potential lack of sensitivity of DBS compared to serum from venous blood and to minimize the risk of false negatives, which would have been detrimental to the interests of the participants. However, for HBsAg, the results that we were subsequently able to verify on venous blood were consistent with the thresholds provided by the manufacturer for the LIAISON® XL Murex HBsAg Quant kit (DiaSorin). We have therefore considered the thresholds for HBsAg as follows, in accordance with the recommendations of the manufacturers of the kits used: reactive (positive) result if index value ≥1.00, non-reactive (negative) result if index value <1.00. Accordingly, for anti-HCV antibodies, we revised the initially broader cutoffs to bring them closer to the manufacturer’s recommendations for the LIAISON® XL MUREX HCV Ab assay (DiaSorin): non-reactive if S/CO <0.80, equivocal if 0.80–1.00, and reactive if ≥1.00. However, because the assay was performed on DBS eluates, we retained a slightly broader equivocal range, classifying results between >0.20 and <1.00 as equivocal. This has changed the number of participants in the “HBsAg+” and “HCV+” columns in Tables 1 and 2. We have therefore modified the corresponding numbers in the manuscript text as well as in Additional Tables 2 and 3 (where the modified elements are highlighted in yellow). Overall, we reviewed all serological cutoff values used in the study and clarified the laboratory procedures in the revised manuscript, specifically in the Materials and Methods section. In addition, detailed information on assay thresholds has been added to Supplementary Table 2. Reviewer #1: The authors performed a seroprevalence study of hepatitis B, C and D and HIV, in the border between French Guiana and Suriname. Some concerns need to be addressed before acceptance of this manuscript. We sincerely thank reviewer #1 for their insightful comments and questions, which we will attempt to address below point by point. 1. The results show an apparent low prevalence of HBsAg in the Amerindian ethnic group. This may be due to the low number of individuals from this ethnic group, in addition to the age of the participants: higher HBsAg prevalence may have been found at lower ages. It would be interesting to include in Table 1 anti-HBc prevalence and perform the analysis of risk factors for HBV according to this marker and not (only) to HBsAg. The presence of anti-HBc is only presented in a supplemental table. Notably, the vaccination uptake in the Amerindian group was significantly higher than in the non-Amerindian group. Consequently, in the first paragraph of the results, we removed results that were redundant with Table 1 and replaced them with results comparing the sociodemographic characteristics (age, sex, education) of vaccinated and unvaccinated participants. We agree with the reviewer to include risk factors for HBV exposure based on anti-HBc seropositivity (regardless of HBsAg status) and have added these description to Tables 1 and 2. As the reviewer correctly noted, exploring HBV infection risk factors only in patients with acute or chronic infection (based on HBsAg positivity) was not the most appropriate, as it does not consider infected individuals who have cleared the infection - a significant proportion of those exposed to the virus, particularly adults [Hepatitis B WHO fact sheets]. We therefore revised the HBV risk factor analyses, initially performed only on individuals with positive HBsAg, with an analysis comparing individuals who were HBV exposed to HBV susceptible individuals, which is not only more relevant from a disease history perspective, but also allows us to present much more robust models, due to the larger number of events. 2. Additional Table 2. Footnote is incomplete: some superscript symbols (*, for example), are not explained in the footnote. We thank the reviewer for their vigilance. We have completed the footnotes for Additional Table 2, corrected “HBe Ab”, which was a typo, to “HBe Ag”, and made changes to the numbers in some cells (highlighted in yellow) following the redefinition of certain thresholds as explained at the beginning of this document: - we initially indicated “‡ 5/52 positive were later tested on whole blood samples and confirmed negative”, but we removed this sentence because these 5 participants had in fact negative HBs Ag with the new threshold definition we describe at the beginning of the document, and replaced with the following precision “‡ 7/46 positive were later tested on whole blood samples and confirmed positive” - “† 3/17 [Anti-HCV Ab] positive were later tested on whole blood samples and confirmed negative” was changed to “4 [Anti-HCV Ab] positives were not retested and 1 was already known and treated” - “* 3/9 equivocal anti-HCV Ab were later tested on whole blood samples and confirmed negative” was changed to “* 4/12 equivocal anti-HCV Ab were later tested on whole blood samples and confirmed negative”. 3. According to Additional Table 2, the prevalence of anti-HBc is indeed quite high, not reflected in the prevalence of HBsAg. It is important to analyze this (high) prevalence of exposure in each population group and to correlate with the risk factors. This is even more important than the correlation with HBsAg. Please see our response to comment 1. We agree with the reviewer and, in addition to modifying the analysis of HBV infection risk factors to include not only HBsAg-positive participants but also anti-HBc-positive participants, we also performed subgroup analyses by sex and by language community, the detailed results of which have been added in Additional Tables 4 and 5, respectively. 4. Did the authors consider to analyze occult HBV infection in at least part of the anti-HBc positive samples? This is a very valid point. However, occult hepatitis B infection (OBI) is defined by the persistence of HBV DNA in the absence of detectable HBsAg. By nature, the viral load is extremely low, usually below 200 IU/mL, and often at the level of 10–50 IU/mL, sometimes detectable only intermittently with highly sensitive PCR assays. Given that the threshold for detection of HBV DNA assays performed on dried blood spots (DBS) is approximately 50-fold higher than that of plasma-based molecular methods, the probability of detecting such low and fluctuating levels of viremia becomes negligible. As a result, DBS testing is not appropriate for the diagnosis or monitoring of OBI, since it would systematically underestimate the true prevalence, Therefore, HBV DNA testing on DBS cannot be recommended for the evaluation of occult hepatitis B, as it lacks the analytical sensitivity required to capture the very low viral loads that define this condition. Furthermore, we know that anti-HBs is less sensitive on DBS, therefore per WHO recommendations we have included only anti-HB-core positive results as part of resolved HBV infections. It is not appropriate for diagnosis or monitoring of occult HBV infections (OBI; defined by persistence of HBV DNA in the absence of HBsAg) since HBV loads in case of OBI are generally extremely low, and not detected by molecular DBS testing. Hence, we may have missed OBI. However, we have added OBI as a limitation to the manuscript: “Fifth, as low level HBV DNA is difficult to detect using DBS, we were unable to collect data on occult HBV infection - defined as presence of HBV DNA in the liver with detectable or undetectable HBV DNA levels in serum, in individuals who are HBsAg seronegative) (EASL 2017 Guidelines). In terms of public health, and prevention of HBV transmission, this aspect warrants further research”. 5. Another concern is the presence of false positive results in these population groups. In rural populations, the presence of polyclonal activation might be frequent, due for example to parasitic infections. This may lead to false positive antibody results, less expected for anti-HBc, which is an inhibition assay (then more specific) but relatively frequent with anti-HCV in some population groups (see for example Rogers KJ, et al., J Clin Lab Anal. 2023 Apr;37(7):e24887. doi: 10.1002/jcla.24887. Epub 2023 Apr 27). The presence of only 20% of viremic samples among the anti-HCV positive ones suggest that some false positive results may have occurred. The authors may consider a second testing with another commercial assay or applying a more stringent criteria of positivity based on signal to cutoff ratio. We thank reviewer 1 for this comment, which lead us to carefully review our biological results and, in particular, the thresholds used to interpret these results. As indicated in the introduction to this letter, we had initially set lower thresholds for the detection of anti-HCV antibodies in order to account for the lower sensitivity of DBS compared to serum from venous blood. We were subsequently able to verify on venous blood a few equivocal anti-HCV Ab participant’s result, and they were all confirmed negative. For anti-HCV Ab, we revised the initially broader cutoffs to bring them closer to those indicated by the manufacturer of the LIAISON® XL MUREX HCV Ab kit (DiaSorin): non-reactive (negative) if S/CO value <0.80; equivocal if S/CO value [0.80-1.00], reactive (positive) if S/CO value ≥1.00. After re analyzing the results, we identified five anti HCV positive cases, four of whom also tested positive for HCV RNA which is more consistent with expected HCV serology. 6. Discussion. The comparison between anti-HBc prevalence should be included, and limitation on anti-HCV testing. We have now added the discussion on anti-HBcore seropositivy. Due to the anti-HCV results being in line with expected HCV serology, we no longer view the anti-HCV testing using DBS as a limitation, and did not add this. Reviewer #2: We would like to thank the reviewer for their insightful comments and questions, which we will attempt to address below point by point. 1. Could you clarify the rationale behind offering an "opt-out" for HIV testing, rather than an "opt-in"? We chose opt-out regimens rather than opt-in for HIV testing, because opt-out can substantially increase HIV testing compared to opt-in schemes (Montoy JCC, Dow WH, Kaplan BC. Patient choice in opt-in, active choice, and opt-out HIV screening: randomized clinical trial. BMJ. 2016 Jan 19;352:h6895; doi: https://doi.org/10.1136/bmj.h6895). We have added this clarification and the associated reference to the manuscript by replacing the following sentence: “This opt-out was offered because of our perception that HIV testing might be a factor in not participating.” with “We chose the opt-out option for HIV testing based on data indicating this may increase test acceptance rate [ref].” 2. Did the demographic characteristics of the 6% who opted out differ from those who consented, and how might this have affected the final reported HIV prevalence? We compared the demographic characteristics of the 134 participants who refused the HIV test with the 2152 participants who accepted it. There were no differences in sex, age, professional activity, but there were differences for the following characteristics: - country of birth: there were less participants who refused HIV testing among those born in Suriname (4.2%) compared to participants born in French Guiana (8.8%) or in another country (5.3%), p=0.002. - country of residence: there were less participants who refused HIV testing among those living in Suriname (3.1%) compared to participants living in French Guiana (7.5%) or in another country (6.7%), p=0.002. - school level: HIV testing refusal rate in participants who have been to high school was higher (11.2%) compared to participants who have either never been to school / primary / middle school and higher education, with HIV testing refusal rates of 4.1, 3.8, 6.0 and 6.6%, respectively, p<0.0001. We have included the following sentence to the manuscript in the results section: - Six percent (n=134) participants opted out HIV-testing. There were significant differences in country of birth and residence, and educational level between participants who opted out for HIV testing compared to those that did not. There were no differences in sex, age, work, or other determinants. And in the discussion/limitation section: - Indeed, 6% opted out for HIV-testing and some of them did so declaring they were HIV-positive. However, the opt-out policy presumably led to a high participation rate; the HBV and HCV prevalence is however, likely more accurate than for HIV. Despite the opt-out, we believe that due to the large sample size, the HIV prevalence estimates are robust. 3. How was the question about "transactional sex" phrased by the cultural mediators to distinguish it from formally declared "sex work"? Understanding this operational definition is crucial for interpreting its significance as a risk factor. The specific question that the mediators asked was “The last time you had sex, did you pay your partner or were you paid by your partner?”. This precision appears in our manuscript as the following footnote in Table 2: “Transactional sex was defined as having paid for or having been paid in exchange for sex”. This formulation implied that we were asking specifically about money and not gifts, compared to what has been done by other authors, for example Ranganathan et al. in young women in rural South Africa, where they distinguished receiving money and gifts in 2 separate questions. In our study, because of the design (same questionnaire for both women and men) and setting, we preferred to use a single succinct question, so as not to overload the questionnaire, which could have slowed down inclusions and discouraged some people from participating. Moreover, this questionnaire was developed based on an extensive preliminary assessment in the communities, including focus group discussions and interviews with key individuals. We believe that the questionnaire was therefore tailored to the population. However, distinguishing sex work and transactional sex, as well as the nuance between money and gifts is interesting, and it might be worthwhile to explore these issues in a more focused project on the Maroni river, especially among girls and young women. 4. The supporting information notes that some initial positive results from Dried Blood Spots were later found to be negative on whole blood samples. Were the final prevalence figures and risk factor analyses based on the initial screening results or only on the confirmed cases? As indicated in the introduction to this letter, we had initially set lower thresholds for the detection of HBsAg and anti-HCV antibodies than the thresholds provided by the manufacturer for the LIAISON® XL Murex HBsAg Quant kit (DiaSorin) in order to account for the potential lack of sensitivity of DBS compared to serum from venous blood and to minimize the risk of false negatives, which would have been detrimental to the interests of the participants. However, for HBsAg, the results that we were subsequently able to verify on venous blood were consistent with the thresholds provided by DiaSorin. We have therefore considered the thresholds for HBsAg as follows, in accordance with the recommendations of the manufacturers of the kits used: reactive (positive) result if index value ≥1.00, non-reactive (negative) result if index value <1.00. For anti-HCV Ab, the manufacturer of the LIAISON® XL MUREX HCV Ab kit (DiaSorin) indicate the following thresholds: non-reactive (negative) if S/CO value <0.80; equivo Submitted filename: 2026.01.14 Response to reviewers.docx 18 Feb 2026 A cross-border seroprevalence study on HBV, HCV, HDV and HIV in remote Amazonian communities on the border between French Guiana and Suriname PONE-D-25-23462R2 Dear Dr. Schaub, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Getu Girmay Academic Editor PLOS One Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #3: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #3: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #3: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #3: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #3: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: After revising the response to the concerns and the revised version, I am pleased to inform that all the concerns have been addressed satisfactorely. Reviewer #3: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #3: No ********** PONE-D-25-23462R2 PLOS One Dear Dr. Schaub, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Mr. Getu Girmay Academic Editor PLOS One